A Phase 4 interventional study of Valsartan 320 mg and Amlodipine 10 mg in Hypertension, sponsored by Novartis. Completed at 1 site in Switzerland. Open to female participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-06-06.
Sponsored by Novartis · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 84th largest by enrollment of the 139 interventional ones that give a count, is one of 13 that started in 2003, is one of 67 in phase 4, and was the 7th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 50 Years to 75 Years · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 13 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
228 studies in Hypertension by Novartis: 5 open now, 6 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 228 studies in Hypertension by Novartis, this one is the 151st largest by enrollment of the 223 interventional ones that give a count, is one of 11 that started in 2003, is one of 67 in phase 4, and was the 12th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 228 in Hypertension:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is compare treatment with valsartan with the possible addition of a diuretic, hydrochlorothiazide, on high blood pressure with the drug amlodipine with the possible addition of a diuretic, hydrochlorothiazide. In particular, the effect of treatment on the stiffness of the blood vessels will be studied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Valsartan 320 mg · Drug: Hydrochlorothiazide
Drug: Amlodipine 10 mg · Drug: Hydrochlorothiazide
Patients received 160 mg valsartan for 4 weeks. Patients were then up-titrated to receive either 320 mg valsartan for the following 8 weeks.
Patients received 5 mg amlodipine for four weeks. Patients were then up-titrated to receive 10 mg amlodipine for the following 8 weeks.
At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure \< 140 mmHg and Diastolic Blood Pressure \< 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.
Change From Baseline to Week 38 in the Carotid-femoral Pulse Wave Velocity (PWV)
PWV was determined from transcutaneous Doppler flow recordings and the foot-to-foot method triggered by the simultaneous ECG. Two simultaneous Doppler flow tracings were taken at the left common carotid and the right femoral artery in the groin with a linear array probe. The time delay (t) was measured between R wave of the ECG and the base of the flow waves recorded at these points, and averaged over 10 beats. The distance (D) traveled by the pulse wave was measured over body surface as the distance from the suprasternal notch to the carotid artery. PWV was calculated as PWV=D/t.
Time frame: Baseline and Week 38
Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Week 12
Cutaneous blood flow was continuously recorded by a laser Doppler flowmeter. The laser Doppler flow probe was applied on the volar part of the right forearm with a plastic holder 10 cm proximal to the wrist. All measurements were made with a pressure cuff on the arm and inflated 20 mmHg above systolic BP and maintained for 2 min then rapidly deflated. All measurements were made in a quiet room with a patient in the supine position. The maximal reactive hyperemia was measured after cuff deflation, which allows measurement of the right forearm postischemic skin reactive hyperemia (SRH).
Time frame: Baseline and Week 12
Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Endpoint (Week 38)
Cutaneous blood flow was continuously recorded by a laser Doppler flowmeter. The laser Doppler flow probe was applied on the volar part of the right forearm with a plastic holder 10 cm proximal to the wrist. All measurements were made with a pressure cuff on the arm and inflated 20 mmHg above systolic BP and maintained for 2 min then rapidly deflated. All measurements were made in a quiet room with a patient in the supine position. The maximal reactive hyperemia was measured after cuff deflation, which allows measurement of the right forearm postischemic skin reactive hyperemia (SRH).
Time frame: Week 38
Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at Week 12
Endothelial function will be assessed using high-resolution duplex ultrasound with wall tracking to measure FMD of the brachial artery during reactive hyperemia. FMD of the brachial artery in response to reactive hyperemia in the distal forearm (and glyceryl trinitrate as a non-endothelium dependent control) will be measured from B-mode ultrasound images using a standard 7 MHz linear array transducer and HDI 5000 system with edge detection.
Time frame: Baseline and Week 12
Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at End-point (Week 38)
Endothelial function will be assessed using high-resolution duplex ultrasound with wall tracking to measure FMD of the brachial artery during reactive hyperemia. FMD of the brachial artery in response to reactive hyperemia in the distal forearm (and glyceryl trinitrate as a non-endothelium dependent control) will be measured from B-mode ultrasound images using a standard 7 MHz linear array transducer and HDI 5000 system with edge detection.
Time frame: Baseline and Week 38
Changes in Mean Left Carotid Distensibility at Week 12
For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe. Absolute diameter and diameter changes over the cardiac cycles will be recorded. Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.
Time frame: Baseline and Week 12
Changes in Mean Left Carotid Distensibility at Week 38
For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe. Absolute diameter and diameter changes over the cardiac cycles will be recorded. Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.
Time frame: Baseline and Week 38
Changes in Mean Right Carotid Distensibility at Week 12
For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe. Absolute diameter and diameter changes over the cardiac cycles will be recorded. Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.
Time frame: Baseline and Week 12
Changes in Mean Right Carotid Distensibility at Week 38
For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe. Absolute diameter and diameter changes over the cardiac cycles will be recorded. Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.
Time frame: Baseline and Week 38
Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 12
The calculation of spontaneous baroflex sensitivity was obtained by the sequence method. Baroflex sequences are defined by at least three consecutive beats in which the systolic blood pressure and the RR interval of the following beat either both increased or decreased. The slope of each individual sequence is computed and the mean slope is determined as the average of all slopes within a given period of time and taken as the gain of the cardiac baroflex (BRSs).
Time frame: Baseline and Week 12
Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 38
The calculation of spontaneous baroflex sensitivity was obtained by the sequence method. Baroflex sequences are defined by at least three consecutive beats in which the systolic blood pressure and the RR interval of the following beat either both increased or decreased. The slope of each individual sequence is computed and the mean slope is determined as the average of all slopes within a given period of time and taken as the gain of the cardiac baroflex (BRSs).
Time frame: Baseline and Week 38
Change in Left Ventricular Mass Index (LVMI) and Diastolic Function Using Echocardiography From Baseline to Week 38
Time frame: Baseline and Week 38
Changes in Central Blood Pressure, Evaluated by Applanation Tonometry From Baseline at Weeks 12 and 38
Central Blood Pressure was measured via applanation tonometry recordings of the common carotid artery and from brachial oscillometric recordings. The Simultaneously obtained carotid artery pressure and standard brachial artery blood pressure are computed to obtain the central systolic pressure.
Time frame: Baseline, Week 12 and Week 38
| Milestone | Valsartan 320 mg | Amlodipine 10 mg |
|---|---|---|
| Started | 63 | 62 |
| Completed | 53 | 50 |
| Not completed | 10 | 12 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Patient withdrew consent | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Adverse event | 8 | 8 |
| Withdrew: Condition no longer required study drug | 0 | 1 |
PWV was determined from transcutaneous Doppler flow recordings and the foot-to-foot method triggered by the simultaneous ECG. Two simultaneous Doppler flow tracings were taken at the left common carotid and the right femoral artery in the groin with a linear array probe. The time delay (t) was measured between R wave of the ECG and the base of the flow waves recorded at these points, and averaged over 10 beats. The distance (D) traveled by the pulse wave was measured over body surface as the distance from the suprasternal notch to the carotid artery. PWV was calculated as PWV=D/t.
| m/s | Valsartan 320 mg | Amlodipine 10 mg |
|---|---|---|
| Change From Baseline to Week 38 in the Carotid-femoral Pulse Wave Velocity (PWV) | -1.9 ± 0.29 | -1.7 ± 0.30 |
Cutaneous blood flow was continuously recorded by a laser Doppler flowmeter. The laser Doppler flow probe was applied on the volar part of the right forearm with a plastic holder 10 cm proximal to the wrist. All measurements were made with a pressure cuff on the arm and inflated 20 mmHg above systolic BP and maintained for 2 min then rapidly deflated. All measurements were made in a quiet room with a patient in the supine position. The maximal reactive hyperemia was measured after cuff deflation, which allows measurement of the right forearm postischemic skin reactive hyperemia (SRH).
| Perfusion units | Valsartan 320 mg | Amlodipine 10 mg |
|---|---|---|
| Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Week 12 | 25.4 ± 14.88 | -105.6 ± 15.31 |
Cutaneous blood flow was continuously recorded by a laser Doppler flowmeter. The laser Doppler flow probe was applied on the volar part of the right forearm with a plastic holder 10 cm proximal to the wrist. All measurements were made with a pressure cuff on the arm and inflated 20 mmHg above systolic BP and maintained for 2 min then rapidly deflated. All measurements were made in a quiet room with a patient in the supine position. The maximal reactive hyperemia was measured after cuff deflation, which allows measurement of the right forearm postischemic skin reactive hyperemia (SRH).
| Perfusion units | Valsartan 320 mg | Amlodipine 10 mg |
|---|---|---|
| Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Endpoint (Week 38) | -9.7 ± 13.73 | -94.6 ± 14.20 |
Endothelial function will be assessed using high-resolution duplex ultrasound with wall tracking to measure FMD of the brachial artery during reactive hyperemia. FMD of the brachial artery in response to reactive hyperemia in the distal forearm (and glyceryl trinitrate as a non-endothelium dependent control) will be measured from B-mode ultrasound images using a standard 7 MHz linear array transducer and HDI 5000 system with edge detection.
| percent | Valsartan 320 mg | Amlodipine 10 mg |
|---|---|---|
| Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at Week 12 | -8.7 ± 0.35 | -8.6 ± 0.38 |
Endothelial function will be assessed using high-resolution duplex ultrasound with wall tracking to measure FMD of the brachial artery during reactive hyperemia. FMD of the brachial artery in response to reactive hyperemia in the distal forearm (and glyceryl trinitrate as a non-endothelium dependent control) will be measured from B-mode ultrasound images using a standard 7 MHz linear array transducer and HDI 5000 system with edge detection.
| percent | Valsartan 320 mg | Amlodipine 10 mg |
|---|---|---|
| Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at End-point (Week 38) | -8.1 ± 0.53 | -8.2 ± 0.56 |
For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe. Absolute diameter and diameter changes over the cardiac cycles will be recorded. Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.
| percent | Valsartan 320 mg | Amlodipine 10 mg |
|---|---|---|
| Changes in Mean Left Carotid Distensibility at Week 12 | 0.0 ± 0.14 | 0.0 ± 0.15 |
For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe. Absolute diameter and diameter changes over the cardiac cycles will be recorded. Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.
| percent | Valsartan 320 mg | Amlodipine 10 mg |
|---|---|---|
| Changes in Mean Left Carotid Distensibility at Week 38 | 0.0 ± 0.16 | 0.1 ± 0.16 |
For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe. Absolute diameter and diameter changes over the cardiac cycles will be recorded. Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.
| percent | Valsartan 320 mg | Amlodipine 10 mg |
|---|---|---|
| Changes in Mean Right Carotid Distensibility at Week 12 | -0.4 ± 0.16 | 0.1 ± 0.17 |
For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe. Absolute diameter and diameter changes over the cardiac cycles will be recorded. Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.
| percent | Valsartan 320 mg | Amlodipine 10 mg |
|---|---|---|
| Changes in Mean Right Carotid Distensibility at Week 38 | -0.2 ± 0.17 | 0.0 ± 0.17 |
The calculation of spontaneous baroflex sensitivity was obtained by the sequence method. Baroflex sequences are defined by at least three consecutive beats in which the systolic blood pressure and the RR interval of the following beat either both increased or decreased. The slope of each individual sequence is computed and the mean slope is determined as the average of all slopes within a given period of time and taken as the gain of the cardiac baroflex (BRSs).
| EP | Valsartan 320 mg | Amlodipine 10 mg |
|---|---|---|
| Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 12 | 1.5 ± 1.71 | -1.5 ± 1.78 |
The calculation of spontaneous baroflex sensitivity was obtained by the sequence method. Baroflex sequences are defined by at least three consecutive beats in which the systolic blood pressure and the RR interval of the following beat either both increased or decreased. The slope of each individual sequence is computed and the mean slope is determined as the average of all slopes within a given period of time and taken as the gain of the cardiac baroflex (BRSs).
| EP | Valsartan 320 mg | Amlodipine 10 mg |
|---|---|---|
| Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 38 | -2.0 ± 1.38 | 0.1 ± 1.44 |
| percent | Valsartan 320 mg | Amlodipine 10 mg |
|---|---|---|
| Change in Left Ventricular Mass Index (LVMI) and Diastolic Function Using Echocardiography From Baseline to Week 38 | -4.8 ± 2.43 | -6.2 ± 2.13 |
Central Blood Pressure was measured via applanation tonometry recordings of the common carotid artery and from brachial oscillometric recordings. The Simultaneously obtained carotid artery pressure and standard brachial artery blood pressure are computed to obtain the central systolic pressure.
| mm Hg | Valsartan 320 mg | Amlodipine 10 mg |
|---|---|---|
| Week 12 | -9.1 ± 1.06 | -14.2 ± 1.10 |
| Week 36 | -11.1 ± 1.07 | -13.9 ± 1.12 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valsartan 320 mg | — | 2/63 (3.2%) | 35/63 (55.6%) |
| Amlodipine 10 mg | — | 2/62 (3.2%) | 51/62 (82.3%) |
| Event | Valsartan 320 mg | Amlodipine 10 mg |
|---|---|---|
| DiplopiaEye disorders | 0/63 | 1/62 |
| Cerebrovascular accidentNervous system disorders | 0/63 | 1/62 |
| Laryngeal oedemaRespiratory, thoracic and mediastinal disorders | 0/63 | 1/62 |
| SyncopeNervous system disorders | 1/63 | 0/62 |
| Transient ischaemic attackNervous system disorders | 1/63 | 0/62 |
| Event | Valsartan 320 mg | Amlodipine 10 mg |
|---|---|---|
| Oedema peripheralGeneral disorders | 9/63 | 48/62 |
| BronchitisInfections and infestations | 8/63 | 0/62 |
| HeadacheNervous system disorders | 6/63 | 5/62 |
| AstheniaGeneral disorders | 5/63 | 2/62 |
| HypotensionVascular disorders | 5/63 | 0/62 |
| FatigueGeneral disorders | 0/63 | 4/62 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 2/63 | 4/62 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/63 | 4/62 |
| VertigoEar and labyrinth disorders | 4/63 | 2/62 |
| InsomniaPsychiatric disorders | 4/63 | 1/62 |
| Age Continuous(years) | Valsartan 320 mg | Amlodipine 10 mg | Total |
|---|---|---|---|
| Mean | 62.3 ± 5.76 | 60.4 ± 5.08 | 61.4 ± 5.50 |
| Sex: Female, Male(Participants) | Valsartan 320 mg | Amlodipine 10 mg | Total |
|---|---|---|---|
| Female | 63 | 62 | 125 |
| Male | 0 | 0 | 0 |
The record gives a start of Sep 2003, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valsartan · Amlodipine